The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Author:

Campo Elias1ORCID,Jaffe Elaine S.2ORCID,Cook James R.3ORCID,Quintanilla-Martinez Leticia4ORCID,Swerdlow Steven H.5,Anderson Kenneth C.6,Brousset Pierre7ORCID,Cerroni Lorenzo8,de Leval Laurence9,Dirnhofer Stefan10,Dogan Ahmet11ORCID,Feldman Andrew L.12ORCID,Fend Falko4,Friedberg Jonathan W.13,Gaulard Philippe1415,Ghia Paolo16ORCID,Horwitz Steven M.17,King Rebecca L.12,Salles Gilles17ORCID,San-Miguel Jesus18ORCID,Seymour John F.19ORCID,Treon Steven P.6ORCID,Vose Julie M.20ORCID,Zucca Emanuele21ORCID,Advani Ranjana22,Ansell Stephen23,Au Wing-Yan24,Barrionuevo Carlos25ORCID,Bergsagel Leif26ORCID,Chan Wing C.27,Cohen Jeffrey I.28,d’Amore Francesco29,Davies Andrew30ORCID,Falini Brunangelo31ORCID,Ghobrial Irene M.632ORCID,Goodlad John R.33ORCID,Gribben John G.34ORCID,Hsi Eric D.35ORCID,Kahl Brad S.36ORCID,Kim Won-Seog37,Kumar Shaji23ORCID,LaCasce Ann S.6ORCID,Laurent Camille7,Lenz Georg38,Leonard John P.39,Link Michael P.40,Lopez-Guillermo Armando41,Mateos Maria Victoria42ORCID,Macintyre Elizabeth43ORCID,Melnick Ari M.44ORCID,Morschhauser Franck45ORCID,Nakamura Shigeo46,Narbaitz Marina47,Pavlovsky Astrid48,Pileri Stefano A.49ORCID,Piris Miguel50ORCID,Pro Barbara51,Rajkumar Vincent12,Rosen Steven T.52,Sander Birgitta53,Sehn Laurie54,Shipp Margaret A.6ORCID,Smith Sonali M.55ORCID,Staudt Louis M.56,Thieblemont Catherine5758,Tousseyn Thomas59,Wilson Wyndham H.56,Yoshino Tadashi60,Zinzani Pier-Luigi61ORCID,Dreyling Martin62ORCID,Scott David W.54ORCID,Winter Jane N.63,Zelenetz Andrew D.1764ORCID

Affiliation:

1. 1Haematopathology Section, Hospital Clínic of Barcelona, Institut d’Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Barcelona, Spain;

2. 2Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD;

3. 3Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH;

4. 4Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany;

5. 5Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA;

6. 6Dana-Farber Cancer Institute, Boston, MA;

7. 7Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d’Excellence Toulouse Cancer, Toulouse, France;

8. 8Department of Dermatology, Medical University of Graz, Graz, Austria;

9. 9Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland;

10. 10Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland;

11. 11Laboratory of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY;

12. 12Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;

13. 13Wilmot Cancer Institute, University of Rochester, Rochester, NY;

14. 14Department of Pathology, University Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France;

15. 15Mondor Institute for Biomedical Research, INSERM U955, Faculty of Medicine, University of Paris-Est Créteil, Créteil, France;

16. 16Strategic Research Program on Chronic Lymphocytic Leukemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy;

17. 17Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;

18. 18Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, CIBERONC, Pamplona, Spain;

19. 19Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;

20. 20Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, University of Nebraska, Omaha, NE;

21. 21Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, and Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland;

22. 22Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford University, Stanford, CA;

23. 23Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;

24. 24Blood-Med Clinic, Hong Kong, People’s Republic of China;

25. 25Department of Pathology, Instituto Nacional de Enfermedades Neoplásicas, Faculty of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru;

26. 26Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ;

27. 27Department of Pathology, City of Hope National Medical Center, Duarte, CA;

28. 28Medical Virology Section, Laboratory of Infectious Diseases, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD;

29. 29Department of Hematology, Aarhus University Hospital, Aarhus, Denmark;

30. 30Cancer Research UK Centre, Centre for Cancer Immunology, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom;

31. 31Institute of Hematology and Center for Hemato-Oncology Research, Hospital of Perugia, University of Perugia , Perugia, Italy;

32. 32Harvard Medical School, Harvard University, Boston, MA;

33. 33National Health Service Greater Glasgow and Clyde, Glasgow, United Kingdom;

34. 34Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;

35. 35Department of Pathology, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, NC;

36. 36Oncology Division, Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO;

37. 37Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;

38. 38Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany;

39. 39Weill Department of Medicine, Weill Medical College, Cornell University, New York, NY;

40. 40Department of Pediatrics, Division of Pediatric Hematology-Oncology, Stanford University School of Medicine, Stanford University, Stanford, CA;

41. 41Department of Hematology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain;

42. 42Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Universidad de Salamanca, Salamanca, Spain;

43. 43Laboratoire d’Onco-Hématologie, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris Cité and Institut Necker-Enfants Malades, Paris, France;

44. 44Division of Hematology and Oncology, Weill Medical College, Cornell University, New York, NY;

45. 45Department of Hematology, Centre Hospitalier Universitaire de Lille, University Lille, Lille, France;

46. 46Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan;

47. 47Department of Pathology, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina and Fundacion para combatir la leucemia (FUNDALEU), Buenos Aires, Argentina;

48. 48Fundación para Combatir la Leucemia (FUNDALEU), Centro de Hematología Pavlovsky, Buenos Aires, Argentina;

49. 49Haematopathology Division, IRCCS, Istituto Europeo di Oncologia, Milan, Italy;

50. 50Jiménez Díaz Foundation University Hospital, Universidad Autónoma de Madrid, Madrid, Spain;

51. 51Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL;

52. 52Beckman Research Institute, and Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;

53. 53Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;

54. 54Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;

55. 55Section of Hematology/Oncology, University of Chicago, Chicago, IL;

56. 56Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;

57. 57Service Hémato-Oncologie, AP-HP, Hôpital Saint-Louis, Paris, France;

58. 58DMU-DHI, Université de Paris-Paris Diderot, Paris, France;

59. 59Department of Pathology, Universitair Ziekenhuis Leuven Hospitals, Leuven, Belgium;

60. 60Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan;

61. 61Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy;

62. 62Department of Medicine III, Ludwig-Maximilians-University Hospital, Munich, Germany;

63. 63Feinberg School of Medicine, Northwestern University, Chicago, IL; and

64. 64Weill Medical College, Cornell University, New York, NY

Abstract

AbstractSince the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3